Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Designing and testing a prophylactic vaccine against HSV-2

FY 2023-24

Summary
Herpes simplex virus type 2 (HSV-2) is a lifelong, sexually transmitted infection that disproportionately affects women and people in African countries. Infection results in painful genital lesions for adults and probable death when vertically transmitted to infants. Furthermore, HSV-2 infection increases susceptibility to serious comorbidities including HIV and encephalitis. Despite several previous HSV-2 vaccine candidates reaching clinical trials, no prophylactic or therapeutic vaccines are currently available. Problems faced by previous vaccine candidates include insufficient immune stimulation and antibody production, failure to produce long-term anti-HSV-2 immunity, and immune evasion by the virus upon natural infection. Recently, an mRNA-based vaccine by BioNTech has entered Phase I clinical trial, but there is a need for several vaccine strategies to combat HSV-2 and related comorbidities. For instance, the accessibility of mRNA vaccines may be impacted by complex storage requirements compared to other vaccine types, which also have more established production networks. Taking difficulties of past vaccine trials and global health needs into account, we intend to develop and test a vaccine for prophylactic use against HSV-2 in an established mouse model of infection. This vaccine will incorporate viral vector and viral-like particle technologies, which are established for use in Ebola and human papillomavirus vaccines respectively. Viral vectors are known to induce long-lasting immunity, while viral-like particles generate strong antibody responses. As well, we will incorporate multiple HSV-2 antigens to address immune evasion. Ultimately, several complementary vaccines are needed to reduce the health burden associated with HSV-2 infection.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506286
Name
Pornsinsiriruk Vannavee
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Designing and testing a prophylactic vaccine against HSV-2
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Global Health; Herpes Simplex Virus Type 2; Mouse Models Of Infection; Mucosal Immunology; Preclinical Studies; Sexually Transmitted Infections; Vaccine Development; Viral Vector Vaccines; Virology; Women'S Health
Abstract
Herpes simplex virus type 2 (HSV-2) is a lifelong, sexually transmitted infection that disproportionately affects women and people in African countries. Infection results in painful genital lesions for adults and probable death when vertically transmitted to infants. Furthermore, HSV-2 infection increases susceptibility to serious comorbidities including HIV and encephalitis. Despite several previous HSV-2 vaccine candidates reaching clinical trials, no prophylactic or therapeutic vaccines are currently available. Problems faced by previous vaccine candidates include insufficient immune stimulation and antibody production, failure to produce long-term anti-HSV-2 immunity, and immune evasion by the virus upon natural infection. Recently, an mRNA-based vaccine by BioNTech has entered Phase I clinical trial, but there is a need for several vaccine strategies to combat HSV-2 and related comorbidities. For instance, the accessibility of mRNA vaccines may be impacted by complex storage requirements compared to other vaccine types, which also have more established production networks. Taking difficulties of past vaccine trials and global health needs into account, we intend to develop and test a vaccine for prophylactic use against HSV-2 in an established mouse model of infection. This vaccine will incorporate viral vector and viral-like particle technologies, which are established for use in Ebola and human papillomavirus vaccines respectively. Viral vectors are known to induce long-lasting immunity, while viral-like particles generate strong antibody responses. As well, we will incorporate multiple HSV-2 antigens to address immune evasion. Ultimately, several complementary vaccines are needed to reduce the health burden associated with HSV-2 infection.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pornsinsiriruk, Vannavee
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~